NRC FORM 374
(7-94)

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 07

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

301779

Licensee	
1. Lee's Summit Hospital	In accordance with letter dated August 21, 1996
2. 530 N. Murray Road Lee's Summit, MO 64063	3. License Number 24-24660-01 is amended in its entirety to read as follows:
	4. Expiration Date April 30, 1996
	5. Docket or Reference No. 030-29074

6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License
A. Any byproduct material identified in 10 CFR 35.100	A. Any radiopharmaceutical identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any radiopharmaceutical identified in 10 CFR 35.200 (excluding Xenon-133)	B. As needed
C. Any byproduct material identified in 10 CFR 35.300	C. Any radiopharmaceutical identified in 10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma)	C. As needed
D. Any byproduct material identified in 10 CFR 35.500	D. Sealed sources identified in 10 CFR 35.500	D. As needed
E. Any byproduct material identified in 10 CFR 31.11	E. Prepackaged Kits	E. As needed

9. Authorized Use:

A. Medical use described in 10 CFR 35.100.

01 mc 2 30 50

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-24660-01
Docket or Reference Number
030-29074
Amendment No. 07

9. Authorized Use (Continued)

B. Medical use described in 10 CFR 35.200 (excluding xenon-133).

C. Medical use described in 10 CFR 35.300 (excluding iodine-131 for thyroid carcinoma).

D. Medical use described in 10 CFR 35.500 in devices which have been evaluated and approved for licensing purposes by the U.S. Nuclear Regulatory Commission or an Agreement State.

E. In vitro studies.

CONDITIONS

10. Location of Use: 530 N. Murray Road, Lee's Summit, Missouri.

11. Radiation Safety Officer: John E. Scott, M.D.

12. Authorized Users:

A. John E. Gustafson, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.

B. David E. Huzuka, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.

C. Robert G. Schwegler, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.

D. John E. Scott, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.

E. Stephen R. Kunz, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.

F. Jack L. Stuber, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.

12. Authorized Users (Continued)

G. William M. Chase, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.

H. Gwendolyn R. Arnett, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.

I. Sandra K. Heard, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133) and 31.11.

J. Dennis M. Wilcox, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.

K. Robert Thompson, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma) and 31.11.

L. Richard L. Cronemeyer, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma and 31.11.

M. Owen D. Maddox, M.D., for material in 10 CFR 35.100, 35.200 (excluding xenon-133), 35.300 (excluding iodine-131 for thyroid carcinoma and 31.11.

13. Pursuant to Title 10, Chapter 1, Code of Federal Regulations, Part 40, "Domestic Licensing of Source Material," the licensee is authorized to possess, use, transfer, and import up to 999 kilograms of depleted uranium contained as shielding material in the molybdenum-99/technetium-99m generators authorized by this license.

14. The licensee shall maintain records of information important to safe and effective decommissioning at the address in Condition 10. per the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-24660-01

Docket or Reference Number
030-29074

Amendment No. 07

15. This license is based on the licensee's statements and representations listed below:

A. Letters dated February 20, 1991 (with attachments), August 21, 1992, June 9, 1994 (with attachments) and August 21, 1996.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date November 22, 1996

By _____
Nuclear Materials Licensing Branch, Region III

55

BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

(FOR LFMS USE)
INFORMATION FROM LTS

Program Code: 02120
Status Code: 0
Fee Category: 7C 2B
Exp. Date: 20010430
Fee Comments: CODE 2J
Decom Fin Assur Reqd: N

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED
   Applicant/Licensee: LEE'S SUMMIT HOSPITAL
   Received Date: 960826
   Docket No: 3029074
   Control No.: 301779
   License No.: 24-24660-01
   Action Type: Amendment

2. FEE ATTACHED
   Amount: ~~X~~
   Check No.: ~~X~~

* add'l info
397121 – 55

3. COMMENTS

Signed D. Hensley
Date 9/5/96

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered ( ))

1. Fee Category and Amount: 7C 2B

2. Correct Fee Paid. Application may be processed for:
   Amendment ✓
   Renewal
   License

3. OTHER

Signed SC
Date 9/5/96

SEP 0 9 1996

Log Sep 2 III
Remitter
Check No.
Amount
Fee Category 7C 2B AND
Type of Fee
Date Check Rec'd
Date Completed 9/5/96
By: SC

FEE NOT REQUIRED

96 SEP 11 PM 4:05

Lee's Summit Hospital
HEALTH MIDWEST

August 21, 1996

U. S. Nuclear Regulatory Commission
Regional Licensing Section
801 Warrenville Road
Lisle, IL 60532-4351

Reference: Amendment of License #24-24660-01

Gentlemen:

When our license was renewed in its entirety the last time, we indicated that Nuclear Medicine would be moved from its existing location to a new area. Specific information for this new area was attached with the renewal and was incorporated into our license. The purpose for this letter is to inform you that we have moved into this new area. Please find enclosed the results of the close-out survey performed in the old area. It is our desire to have this area removed as an area of use from our license, as we would like to use this area for other purposes.

If you have any questions concerning the close-out survey results or if we can be of further assistance, please feel free to contact me.

Sincerely,

John L. Jacobson
President and Chief Executive Officer

Continuation of 397121
FEE NOT REQUIRED

RECEIVED
AUG 26 1996
REGION III

PM 8/22/96

30179
AUG 26 1996

530 N.W. Murray Road ■ Lee's Summit, MO 64081 ■ 816/251-7000

CLOSE-OUT SURVEY

LEES SUMMIT HOSPITAL

SCAN ROOM AREA

8/15/96



AREA	mR/Hr	CPM	DPM
1	.03	180	---
2	.03	180	---
3	.03	180	---
4	.03	185	---
5	.03	185	---
6	.03	185	---
7	.03	185	---
8	.03	185	---
9	.03	185	---
10	.03	197	12.8
11	.03	197	12.8
12	.03	197	12.8
13	.03	193	8.1
14	.03	193	8.1
15	.03	193	8.1
16	.03	172	---
17	.03	172	---
18	.03	172	---
BKG	.03	186	

Ray Lamm

SURVEY METER: LUDLUM 14C-4417
CALIBRATED: 6/17/95

WELL COUNTER: PICKER SPECTRASCALER 1T
CALIBRATED: 6/17/95
EFF: 86.4%

CLOSE-OUT SURVEY
LEE'S SUMMIT HOSPITAL
HOT LAB AREA

8/15/96



Eng Lawrence, MO

AREA	mR/Hr	CPM	DPM
1	.03	192	6.9
2	.03	192	6.9
3	.03	192	6.9
4	.03	187	1.2
5	.03	187	1.2
6	.03	187	1.2
7	.03	159	0
8	.03	159	0
9	.03	159	0
10	.03	159	0
BKG	.03	186	---

NOV 25 1996

John L. Jacobson
President/CEO
Lee's Summit Hospital
530 N. Murray Road
Lee's Summit, MO 64063

Dear Mr. Jacobson:

Enclosed is Amendment No. 07 to your NRC Material License No. 24-24660-01 in accordance with your request.

Please review the enclosed document carefully and be sure that you understand all conditions. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region III office at (630) 829-9887 so that we can provide appropriate corrections and answers.

Please be advised that we have released your old nuclear medicine space for unrestricted use.

Please be advised that your license expires at the end of the day, in the month, and year stated in the license. Unless your license has been terminated, you must conduct your program involving byproduct materials in accordance with the conditions of your NRC license, representations made in your license application, and NRC regulations. In particular, note that you must:

1. Operate in accordance with NRC regulations 10 CFR Part 19, "Notices, Instructions and Reports to Workers; Inspections," 10 CFR Part 20, "Standards for Protection Against Radiation," and other applicable regulations.

2. Notify NRC, in writing, within 30 days:

   a. When an authorized user or Radiation Safety Officer permanently discontinues performance of duties under the license or has a name change; or

   b. When the licensee's mailing address changes (no fee is required if the location of byproduct material remains the same).

301779

3. In accordance with 10 CFR 30.36(b) and/or license condition, notify NRC, promptly, in writing, and request termination of the license when you decide to terminate all activities involving materials authorized under the license.

4. Request and obtain a license amendment before you:

   a. Receive or use byproduct material for a clinical procedure permitted under Part 35 but not permitted by your license issued pursuant to this Part;

   b. Permit anyone, except individuals described in 10 CFR 35.13(b), to work as an authorized user under the license;

   c. Change Radiation Safety Officers;

   d. Order byproduct material in excess of the amount, or radionuclide, or form different than authorized on the license;

   e. Add or change the areas of use or address or addresses of use identified in the license application or on the license; or

   f. Change ownership of your organization.

5. Submit a complete renewal application with proper fee or termination request at least 30 days before the expiration date of your license. You will receive a reminder notice approximately 90 days before the expiration date. Possession of byproduct material after your license expires is a violation of NRC regulations. A license will not normally be renewed, except on a case-by-case basis, in instances where licensed material has never been possessed or used.

In addition, please note that NRC Form 313 requires the applicant, by his/her signature, to verify that the applicant understands that all statements contained in the application are true and correct to the best of the applicant's knowledge. The signatory for the application should be the licensee or certifying official rather than a consultant.

You will be periodically inspected by NRC. Failure to conduct your program in accordance with NRC regulations, license conditions, and representations made in your license application and supplemental correspondence with NRC will result in enforcement action against you. This could include issuance of a notice of violation, or imposition of a civil penalty, or an order suspending, modifying or revoking your license as specified in the General Policy and Procedures for NRC Enforcement Actions. Since serious consequences to employees and the public can result from failure to comply with NRC requirements,

prompt and vigorous enforcement action will be taken when dealing with licensees who do not achieve the necessary meticulous attention to detail and the high standard of compliance which NRC expects of its licensees.

Sincerely,

Original Signed By
Gidget Watson
Nuclear Materials Licensing Branch

License No. 24-24660-01
Docket No. 030-29074

Enclosure: Amendment No. 07

DOCUMENT NAME: M:\03029074.CL6
To receive a copy of this document, indicate in the box: "**C**" = Copy without attachment/enclosure "**E**" = Copy with attachment/enclosure "**N**" = No copy

OFFICE	DNMS/RIII								
NAME	GWatson:brt								
DATE	11/22/96 GW								

OFFICIAL RECORD COPY